GLENMARK vs LINCOLN: Stock Comparison
GLENMARK PHARMACEUTICALS is the larger company by market capitalisation. GLENMARK PHARMACEUTICALS shows a higher ROE, faster revenue growth and lower leverage, while LINCOLN PHARMA shows a lower P/E, a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLENMARK leads 7; LINCOLN leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLENMARK | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLENMARK | LINCOLN |
|---|---|---|
| Live Price | ₹2,437.2 | ₹620.8 |
| Day Change | -0.89% | -0.3% |
| Volume | 4.13 L | 29,091 |
| 52-Week High | ₹2,537.6 | ₹770 |
| 52-Week Low | ₹1,792.6 | ₹440 |
| Distance from 52W High | -3.96% | -19.38% |
Valuation
| Metric | GLENMARK | LINCOLN |
|---|---|---|
| Market Cap | ₹68,490 Cr | ₹1,240 Cr |
| P/E Ratio | 46.23x | 12.83x |
| P/B Ratio | 6.58x | 1.63x |
| EPS | ₹26.07 | ₹18.09 |
| Book Value | ₹372.49 | ₹378.25 |
| Dividend Yield | 0.21% | 0.3% |
Growth
| Metric | GLENMARK | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | 14.3% | 11.4% |
| EPS Growth (TTM YoY) | 6,575% | 0.6% |
| Qtr Sales Growth | -39.41% | 0% |
| Qtr Profit Growth | 52.36% | 0% |
Profitability & Leverage
| Metric | GLENMARK | LINCOLN |
|---|---|---|
| ROE | 12.96% | 11.6% |
| ROCE | 18.25% | 11.97% |
| Net Margin | 8.15% | 13.1% |
| Operating Margin | 12.92% | 17.38% |
| Debt to Equity | 0x | 0.01x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GLENMARK | LINCOLN |
|---|---|---|
| Promoter Holding | 46.65% | 49.78% |
| FII Holding | 20.89%▲ 0.55 pp | 4.6%▼ 0.59 pp |
| DII Holding | 18.6%▼ 0.69 pp | 0.27%▼ 0.82 pp |
| Public Holding | 13.81%▲ 0.13 pp | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLENMARK PHARMACEUTICALS and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.